Nabi's PhosLo shown to provide superior control of serum phosphorus in end-stage renal disease

By Lisa Kerner

Charlotte, N.C., July 18 - Nabi Biopharmaceuticals said study results demonstrate that PhosLo (calcium acetate) provides superior control of serum phosphorus compared to sevelamer.

Serum phosphorus is a key determinant of morbidity and mortality among end-stage renal disease (ESRD) patients.

Of the 1,000 initial adult patients in the study, 181 patients were treated exclusively with sevelamer and 321 patients were treated exclusively with calcium acetate, according to a company news release.

Averaged serum phosphorus over the one-year period was 5.05 +/- 1.14 mg/dL in the calcium acetate group and 5.42 +/- 1.22 mg/dL in the sevelamer group.

The study confirms conclusions from Nabi's original CARE study, which produced similar results over an eight-week period.

The findings of the study were presented in poster format at the European Renal Association and the European Dialysis and Transplant Association Congress in Glasgow, Scotland.

Nabi is a biopharmaceutical company located in Boca Raton, Fla.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.